论文部分内容阅读
腹膜透析(peritoneal dialysis,PD)是治疗终末期肾病的重要措施之一。随着PD患者存活时间延长,慢性肾脏病-矿物质和骨异常(chronic kidney disease mineral and bone disorder,CKD-MBD)已经成为影响其生命和生活质量的重要并发症,导致患者心血管及全因死亡率增加。高磷血症是CKD-MBD发生的始动环节。与血液透析患者相比,PD患者的血钙、磷、甲状旁腺素水平相对稳定,更易发生低转运性骨病。这些差异由多种因素导致,其中PD患者的残余肾功能、腹膜转运特点及PD液等因素都会影响PD患者的钙磷代谢,从而影响其CKD-MBD。
Peritoneal dialysis (PD) is one of the important measures in the treatment of end-stage renal disease. Chronic kidney disease, mineral and bone disorder (CKD-MBD) has become an important complication of life and quality of life, leading to cardiovascular and all-cause Mortality increased. Hyperphosphatemia is the initiating link of CKD-MBD. Compared with hemodialysis patients, PD patients with serum calcium, phosphorus, parathyroid hormone levels are relatively stable, more prone to low transport osteogenic disease. These differences are caused by a variety of factors, including residual renal function, PD peritoneal transport characteristics and PD fluid and other factors will affect the metabolism of calcium and phosphorus in patients with PD, which affects its CKD-MBD.